Search Results

You are looking at 101 - 110 of 118 items for :

  • Abstract: Arteries x
  • Abstract: Atherosclerosis x
  • Abstract: Carotid x
  • Abstract: Circulation x
  • Abstract: Ghrelin x
  • Abstract: Veins x
  • Abstract: Heart x
  • Abstract: cardiac* x
  • Abstract: Myocardial x
Clear All Modify Search
Kunal Thakkar Department of Endocrinology, Seth G S Medical College & KEM Hospital, Mumbai, India

Search for other papers by Kunal Thakkar in
Google Scholar
PubMed
Close
,
Swati Ramteke-Jadhav Department of Endocrinology, Seth G S Medical College & KEM Hospital, Mumbai, India

Search for other papers by Swati Ramteke-Jadhav in
Google Scholar
PubMed
Close
,
Rajeev Kasaliwal Department of Endocrinology, Mahatma Gandhi Medical College & Hospital, Jaipur, India

Search for other papers by Rajeev Kasaliwal in
Google Scholar
PubMed
Close
,
Saba Samad Memon Department of Endocrinology, Seth G S Medical College & KEM Hospital, Mumbai, India

Search for other papers by Saba Samad Memon in
Google Scholar
PubMed
Close
,
Virendra Patil Department of Endocrinology, Seth G S Medical College & KEM Hospital, Mumbai, India

Search for other papers by Virendra Patil in
Google Scholar
PubMed
Close
,
Puja Thadani Department of Endocrinology, Seth G S Medical College & KEM Hospital, Mumbai, India

Search for other papers by Puja Thadani in
Google Scholar
PubMed
Close
,
Nilesh Lomte Department of Endocrinology, Seth G S Medical College & KEM Hospital, Mumbai, India

Search for other papers by Nilesh Lomte in
Google Scholar
PubMed
Close
,
Shilpa Sankhe Department of Radiology, Seth G S Medical College & KEM Hospital, Mumbai, India

Search for other papers by Shilpa Sankhe in
Google Scholar
PubMed
Close
,
Atul Goel Department of Neurosurgery, Seth G S Medical College & KEM Hospital, Mumbai, India

Search for other papers by Atul Goel in
Google Scholar
PubMed
Close
,
Sridhar Epari Department of Pathology, Tata Memorial Centre, Mumbai, India

Search for other papers by Sridhar Epari in
Google Scholar
PubMed
Close
,
Naina Goel Department of Neuropathology, Seth G S Medical College & KEM Hospital, Mumbai, India

Search for other papers by Naina Goel in
Google Scholar
PubMed
Close
,
Anurag Lila Department of Endocrinology, Seth G S Medical College & KEM Hospital, Mumbai, India

Search for other papers by Anurag Lila in
Google Scholar
PubMed
Close
,
Nalini S Shah Department of Endocrinology, Seth G S Medical College & KEM Hospital, Mumbai, India

Search for other papers by Nalini S Shah in
Google Scholar
PubMed
Close
, and
Tushar Bandgar Department of Endocrinology, Seth G S Medical College & KEM Hospital, Mumbai, India

Search for other papers by Tushar Bandgar in
Google Scholar
PubMed
Close

Background

Most common incidentally detected sellar-suprasellar region (SSR) masses are pituitary adenomas, followed by craniopharyngioma, rathke’s cleft cyst, hypophysitis, and meningioma. Besides these, certain unusual SSR lesions can sometimes present as diagnostic challenges, where diagnosis is often made post-operatively on histopathology, the pre-operative suspicion of which might have influenced the management strategies. Series describing such masses are few.

Objective

To present clinical, biochemical, and radiological characteristics and management outcomes of rare SSR lesions other than pituitary adenomas, craniopharyngioma, rathke’s cleft cyst, hypophysitis, and meningioma.

Design, setting, patients

Retrospective case record analysis of patients with uncommon SSR masses (from January 2006 to December 2016).

Results

Our series consisted of ten patients, five with neoplastic and five with non-neoplastic lesions. Neoplastic masses included granular cell tumor (n = 2), astrocytoma (n = 1), malignant peripheral nerve sheath tumor (MPNST, n = 1), and metastasis from occult papillary carcinoma of thyroid (n = 1), while non-neoplastic masses were aspergillus abscess (n = 1), sterile abscess (n = 1), and tubercular abscess (n = 1), aneurysm of left internal carotid artery (n = 1), and ruptured dermoid cyst (n = 1). All patients (except one) presented with headache and/or visual disturbance. Only one patient had acromegaly while most others had hypopituitarism. We describe detailed MRI characteristics of each of the lesion. Seven patients underwent trans-sphenoidal surgery. Post-operatively, five patients had permanent diabetes insipidus, while two patients died in early post-operative period.

Conclusion

Our series expand the differential diagnostic considerations of SSR lesions. Most of the rare SSR masses present with symptoms of mass effects and hypopituitarism. Except for some non-neoplastic lesions like sellar abscesses, aneurysms, and dermoid cysts which can have some specific imaging characteristics that can provide clue to pre-operative diagnosis, most of the other neoplastic masses have overlapping radiological features, and pre-operative suspicion remains difficult.

Open access
Ursula M M Costa Division of Cardiology, Division of Endocrinology, Division of Endocrinology, Federal University of Sergipe, Aracaju, SE 49060-100, Brazil

Search for other papers by Ursula M M Costa in
Google Scholar
PubMed
Close
,
Carla R P Oliveira Division of Cardiology, Division of Endocrinology, Division of Endocrinology, Federal University of Sergipe, Aracaju, SE 49060-100, Brazil

Search for other papers by Carla R P Oliveira in
Google Scholar
PubMed
Close
,
Roberto Salvatori Division of Cardiology, Division of Endocrinology, Division of Endocrinology, Federal University of Sergipe, Aracaju, SE 49060-100, Brazil

Search for other papers by Roberto Salvatori in
Google Scholar
PubMed
Close
,
José A S Barreto-Filho Division of Cardiology, Division of Endocrinology, Division of Endocrinology, Federal University of Sergipe, Aracaju, SE 49060-100, Brazil

Search for other papers by José A S Barreto-Filho in
Google Scholar
PubMed
Close
,
Viviane C Campos Division of Cardiology, Division of Endocrinology, Division of Endocrinology, Federal University of Sergipe, Aracaju, SE 49060-100, Brazil

Search for other papers by Viviane C Campos in
Google Scholar
PubMed
Close
,
Francielle T Oliveira Division of Cardiology, Division of Endocrinology, Division of Endocrinology, Federal University of Sergipe, Aracaju, SE 49060-100, Brazil

Search for other papers by Francielle T Oliveira in
Google Scholar
PubMed
Close
,
Ivina E S Rocha Division of Cardiology, Division of Endocrinology, Division of Endocrinology, Federal University of Sergipe, Aracaju, SE 49060-100, Brazil

Search for other papers by Ivina E S Rocha in
Google Scholar
PubMed
Close
,
Joselina L M Oliveira Division of Cardiology, Division of Endocrinology, Division of Endocrinology, Federal University of Sergipe, Aracaju, SE 49060-100, Brazil

Search for other papers by Joselina L M Oliveira in
Google Scholar
PubMed
Close
,
Wersley A Silva Division of Cardiology, Division of Endocrinology, Division of Endocrinology, Federal University of Sergipe, Aracaju, SE 49060-100, Brazil

Search for other papers by Wersley A Silva in
Google Scholar
PubMed
Close
, and
Manuel H Aguiar-Oliveira Division of Cardiology, Division of Endocrinology, Division of Endocrinology, Federal University of Sergipe, Aracaju, SE 49060-100, Brazil

Search for other papers by Manuel H Aguiar-Oliveira in
Google Scholar
PubMed
Close

Abstract

GH and its principal mediator IGF1 have important effects on metabolic and cardiovascular (CV) status. While acquired GH deficiency (GHD) is often associated with increased CV risk, the consequences of congenital GHD are not known. We have described a large group of patients with isolated GHD (IGHD) due to a homozygous mutation (c.57+1G>A) in the GH releasing hormone receptor gene, and shown that adult GH-naïve individuals have no evidence of clinically evident premature atherosclerosis. To test whether subclinical atherosclerosis is anticipated in untreated IGHD, we performed a cross-sectional study of 25 IGHD and 27 adult controls matched for age and gender. A comprehensive clinical and biochemical panel and coronary artery calcium scores were evaluated by multi-detector tomography. Height, weight, IGF1, homeostasis model assessment of insulin resistance, creatinine and creatininekinase were lower in the IGHD group. Median and interquartile range of calcium scores distribution was similar in the two groups: IGHD 0(0) and control 0(4.9). The vast majority of the calcium scores (20 of 25 IGHD (80%) and 18 of 27 controls (66.6%)) were equal to zero (difference not significant). There was no difference in the calcium scores classification. None of IGHD subjects had minimal calcification, which were present in four controls. Three IGHD and four controls had mild calcification. There were two IGHD individuals with moderate calcification and one control with severe calcification. Our study provides evidence that subjects with congenital isolated lifetime and untreated severe IGHD do not have accelerated subclinical coronary atherosclerosis.

Open access
Marko Stojanovic Neuroendocrinology Department, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Centre of Serbia, Belgrade, Serbia
University of Belgrade, Medical Faculty, Belgrade, Serbia

Search for other papers by Marko Stojanovic in
Google Scholar
PubMed
Close
,
Zida Wu Department of Medicine for Endocrinology, Diabetes and Nutritional Medicine, Charité Universitätsmedizin, Campus Mitte, Berlin, Germany

Search for other papers by Zida Wu in
Google Scholar
PubMed
Close
,
Craig E Stiles Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK

Search for other papers by Craig E Stiles in
Google Scholar
PubMed
Close
,
Dragana Miljic Neuroendocrinology Department, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Centre of Serbia, Belgrade, Serbia
University of Belgrade, Medical Faculty, Belgrade, Serbia

Search for other papers by Dragana Miljic in
Google Scholar
PubMed
Close
,
Ivan Soldatovic University of Belgrade, Medical Faculty, Belgrade, Serbia
Insitute of Medical Statistics and Informatics, Belgrade, Serbia

Search for other papers by Ivan Soldatovic in
Google Scholar
PubMed
Close
,
Sandra Pekic Neuroendocrinology Department, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Centre of Serbia, Belgrade, Serbia
University of Belgrade, Medical Faculty, Belgrade, Serbia

Search for other papers by Sandra Pekic in
Google Scholar
PubMed
Close
,
Mirjana Doknic Neuroendocrinology Department, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Centre of Serbia, Belgrade, Serbia
University of Belgrade, Medical Faculty, Belgrade, Serbia

Search for other papers by Mirjana Doknic in
Google Scholar
PubMed
Close
,
Milan Petakov Neuroendocrinology Department, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Centre of Serbia, Belgrade, Serbia
University of Belgrade, Medical Faculty, Belgrade, Serbia

Search for other papers by Milan Petakov in
Google Scholar
PubMed
Close
,
Vera Popovic University of Belgrade, Medical Faculty, Belgrade, Serbia

Search for other papers by Vera Popovic in
Google Scholar
PubMed
Close
,
Christian Strasburger Department of Medicine for Endocrinology, Diabetes and Nutritional Medicine, Charité Universitätsmedizin, Campus Mitte, Berlin, Germany

Search for other papers by Christian Strasburger in
Google Scholar
PubMed
Close
, and
Márta Korbonits Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK

Search for other papers by Márta Korbonits in
Google Scholar
PubMed
Close

Background

Aryl hydrocarbon receptor-interacting protein (AIP) is evolutionarily conserved and expressed widely throughout the organism. Loss-of-function AIP mutations predispose to young-onset pituitary adenomas. AIP co-localizes with growth hormone in normal and tumorous somatotroph secretory vesicles. AIP protein is detectable in circulation. We aimed to investigate possible AIP and GH co-secretion, by studying serum AIP and GH levels at baseline and after GH stimulation or suppression, in GH deficiency (GHD) and in acromegaly patients.

Subjects and methods

Insulin tolerance test (ITT) was performed in GHD patients (n = 13) and age-BMI-matched normal GH axis control patients (n = 31). Oral glucose tolerance test (OGTT) was performed in active acromegaly patients (n = 26) and age-BMI-matched normal GH axis control patients (n = 18). In-house immunometric assay was developed for measuring circulating AIP.

Results

Serum AIP levels were in the 0.1 ng/mL range independently of gender, age or BMI. Baseline AIP did not differ between GHD and non-GHD or between acromegaly and patients with no acromegaly. There was no change in peak, trough or area under the curve during OGTT or ITT. Serum AIP did not correlate with GH during ITT or OGTT.

Conclusions

Human circulating serum AIP in vivo was assessed by a novel immunometric assay. AIP levels were independent of age, sex or BMI and unaffected by hypoglycaemia or hyperglycaemia. Despite co-localization in secretory vesicles, AIP and GH did not correlate at baseline or during GH stimulation or suppression tests. A platform of reliable serum AIP measurement is established for further research of its circulatory source, role and impact.

Open access
Anna C Simcocks Institute for Health and Sport, Victoria University, St Albans campus, Melbourne, Victoria, Australia

Search for other papers by Anna C Simcocks in
Google Scholar
PubMed
Close
,
Kayte A Jenkin Institute for Health and Sport, Victoria University, St Albans campus, Melbourne, Victoria, Australia
School of Science and Health, Western Sydney University, Campbelltown, New South Wales, Australia

Search for other papers by Kayte A Jenkin in
Google Scholar
PubMed
Close
,
Lannie O’Keefe Institute for Health and Sport, Victoria University, St Albans campus, Melbourne, Victoria, Australia

Search for other papers by Lannie O’Keefe in
Google Scholar
PubMed
Close
,
Chrishan S Samuel Cardiovascular Disease Program, Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, Victoria, Australia

Search for other papers by Chrishan S Samuel in
Google Scholar
PubMed
Close
,
Michael L Mathai Institute for Health and Sport, Victoria University, St Albans campus, Melbourne, Victoria, Australia
The Florey Institute of Neuroscience and Mental Health, Parkville, Melbourne, Victoria, Australia

Search for other papers by Michael L Mathai in
Google Scholar
PubMed
Close
,
Andrew J McAinch Institute for Health and Sport, Victoria University, St Albans campus, Melbourne, Victoria, Australia
Australian Institute for Musculoskeletal Science (AIMSS), College of Health and Biomedicine, Victoria University, Melbourne, Victoria, Australia

Search for other papers by Andrew J McAinch in
Google Scholar
PubMed
Close
, and
Deanne H Hryciw Institute for Health and Sport, Victoria University, St Albans campus, Melbourne, Victoria, Australia
School of Environment and Sciences, Griffith University, Nathan, Queensland, Australia

Search for other papers by Deanne H Hryciw in
Google Scholar
PubMed
Close

Atypical cannabinoid compounds O-1602 and O-1918 are ligands for the putative cannabinoid receptors G protein-coupled receptor 55 and G protein-coupled receptor 18. The role of O-1602 and O-1918 in attenuating obesity and obesity-related pathologies is unknown. Therefore, we aimed to determine the role that either compound had on body weight and body composition, renal and hepatic function in diet-induced obesity. Male Sprague–Dawley rats were fed a high-fat diet (40% digestible energy from lipids) or a standard chow diet for 10 weeks. In a separate cohort, male Sprague–Dawley rats were fed a high-fat diet for 9 weeks and then injected daily with 5 mg/kg O-1602, 1 mg/kg O-1918 or vehicle (0.9% saline/0.75% Tween 80) for a further 6 weeks. Our data demonstrated that high-fat feeding upregulates whole kidney G protein receptor 55 expression. In diet-induced obesity, we also demonstrated O-1602 reduces body weight, body fat and improves albuminuria. Despite this, treatment with O-1602 resulted in gross morphological changes in the liver and kidney. Treatment with O-1918 improved albuminuria, but did not alter body weight or fat composition. In addition, treatment with O-1918 also upregulated circulation of pro-inflammatory cytokines including IL-1α, IL-2, IL-17α, IL-18 and RANTES as well as plasma AST. Thus O-1602 and O-1918 appear not to be suitable treatments for obesity and related comorbidities, due to their effects on organ morphology and pro-inflammatory signaling in obesity.

Open access
Theodoros Karampitsakos Third Department of Obstetrics and Gynecology, ATTIKON University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
Unit of Endocrinology, Diabetes Mellitus and Metabolism, ARETAIEION University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Theodoros Karampitsakos in
Google Scholar
PubMed
Close
,
Fotini Kanouta Unit of Endocrinology, Diabetes Mellitus and Metabolism, First Department of Obstetrics and Gynecology, ALEXANDRA University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
Unit of Endocrinology, Diabetes Mellitus and Metabolism, ARETAIEION University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Fotini Kanouta in
Google Scholar
PubMed
Close
,
Christos Chatzakis Second Department of Obstetrics and Gynecology, IPPOKRATEIO General Hospital of Thessaloniki, Aristotle, University of Thessaloniki, Athens, Greece

Search for other papers by Christos Chatzakis in
Google Scholar
PubMed
Close
,
Vassilios Bakoulas Athens, Greece

Search for other papers by Vassilios Bakoulas in
Google Scholar
PubMed
Close
,
Alexandros Gryparis Department of Speech and Language Therapy, University of Ioannina, Ioannina, Greece
Unit of Endocrinology, Diabetes Mellitus and Metabolism, ARETAIEION University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Alexandros Gryparis in
Google Scholar
PubMed
Close
,
Petros Drakakis Third Department of Obstetrics and Gynecology, ATTIKON University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Petros Drakakis in
Google Scholar
PubMed
Close
,
Djuro Macut Department of Endocrinology, Diabetes and Diseases of Metabolism, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Unit of Endocrinology, Diabetes Mellitus and Metabolism, ARETAIEION University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Djuro Macut in
Google Scholar
PubMed
Close
, and
George Mastorakos Unit of Endocrinology, Diabetes Mellitus and Metabolism, ARETAIEION University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by George Mastorakos in
Google Scholar
PubMed
Close

Introduction

To investigate whether synthetic (s) glucocorticoids (GCs) administered between the 24th and the 34th gestational weeks in pre-term labor might precipitate labor, studies on sGCs administration were reviewed. The physiology of endogenous glucocorticoid-related increase in fetal–maternal circulation and its association with labor, followed by a scoping review of studies on exogenous sGCs administered for fetal lung maturation and the timing of labor, were included.

Materials and methods

The methodology of systematic reviews was followed. MEDLINE, Cochrane Library, and Google Scholar databases were searched until October 2023, for original studies investigating the administration of sGCs in pregnancies risking pre-term labor. Duplicates were removed, and 1867 abstracts were excluded as irrelevant. Six controlled and four non-controlled studies were included. The index group consisted of 6001 subjects and 7691 controls in the former, while in the latter, the index group consisted of 2069 subjects.

Results

In three out of the six controlled studies, gestational age at labor was significantly lower in sGC-treated women than in controls, while in three studies, gestational age at labor was lower in sGC-treated women than in controls, with a trend toward statistical significance. In one study, gestational age at labor was significantly lower in controls than in sGC-treated women. In the non-controlled studies, the majority of women delivered less than 1 week from the day of sGC administration.

Conclusions

In this scoping review, studies lack homogeneity. However, in the controlled studies, a pattern of earlier labor emerges among sGC-treated pregnant women. The use of multiple courses of antenatal sGCs appears to be associated with precipitated labor. Their use should be carefully weighed. Carefully designed trials should examine this ongoing scientific query.

Open access
Nese Cinar Department of Endocrinology and Metabolism, Hacettepe University School of Medicine, 06100 Sihhiye, Ankara, Turkey

Search for other papers by Nese Cinar in
Google Scholar
PubMed
Close
and
Alper Gurlek Department of Endocrinology and Metabolism, Hacettepe University School of Medicine, 06100 Sihhiye, Ankara, Turkey

Search for other papers by Alper Gurlek in
Google Scholar
PubMed
Close

Adipose tissue secretes a variety of active biological substances, called adipocytokines, that act in an autocrine, paracrine, and endocrine manner. They have roles in appetite control, thermogenesis, and thyroid and reproductive functions. All these molecules may lead to local and generalized inflammation, mediating obesity-associated vascular disorders including hypertension, diabetes, atherosclerosis, and insulin resistance. Thyroid dysfunction is associated with changes in body weight, thermogenesis, and energy expenditure. The connections between cardiovascular risk factors such as dyslipidemia, impaired glucose tolerance, insulin resistance, atherosclerosis, and thyroid dysfunction have been reported in several studies. The adipocytokines serve as causative or protective factors in the development of these disorders in the states of thyroid dysfunction. Abnormal levels of adipocytokines (adiponectin (ADP), leptin, resistin, vaspin, and visfatin) in hypo- and hyperthyroidism have been reported with controversial results. This review aims to update the implication of novel adipokines ADP, vaspin, and visfatin in thyroid dysfunction.

Open access
Amir H Zamanipoor Najafabadi Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands
Department of Medicine, Division of Endocrinology and Centre for Endocrine Tumors, Leiden University Medical Centre, Leiden, The Netherlands
Department of Neurosurgery, University Neurosurgical Centre Holland (UNCH), Leiden University Medical Centre, Haaglanden Medical Centre and Haga Teaching Hospitals, Leiden and The Hague, The Netherlands

Search for other papers by Amir H Zamanipoor Najafabadi in
Google Scholar
PubMed
Close
,
Merel van der Meulen Department of Medicine, Division of Endocrinology and Centre for Endocrine Tumors, Leiden University Medical Centre, Leiden, The Netherlands

Search for other papers by Merel van der Meulen in
Google Scholar
PubMed
Close
,
Ana Luisa Priego Zurita Department of Medicine, Division of Endocrinology and Centre for Endocrine Tumors, Leiden University Medical Centre, Leiden, The Netherlands

Search for other papers by Ana Luisa Priego Zurita in
Google Scholar
PubMed
Close
,
S Faisal Ahmed Chair of Work Package of E-Health & ICT of Endo-ERN, Developmental Endocrinology Research Group, School of Medicine, Dentistry & Nursing, University of Glasgow and Office for Rare Conditions, Royal Hospital for Children & Queen Elizabeth University Hospital, Glasgow, UK

Search for other papers by S Faisal Ahmed in
Google Scholar
PubMed
Close
,
Wouter R van Furth Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands

Search for other papers by Wouter R van Furth in
Google Scholar
PubMed
Close
,
Evangelia Charmandari Pediatric Chair Main Thematic Group 6 Pituitary of Endo-ERN, Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, National and Kapodistrian University of Athens Medical School, ‘Aghia Sophia’ Children’s Hospital, Athens, Greece

Search for other papers by Evangelia Charmandari in
Google Scholar
PubMed
Close
,
Olaf Hiort Pediatric Chair and Deputy Coordinator of Endo-ERN, Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and Adolescent Medicine, University of Lübeck, Lübeck, Germany

Search for other papers by Olaf Hiort in
Google Scholar
PubMed
Close
,
Alberto M Pereira Adult Chair and Coordinator of Endo-ERN, Department of Endocrinology and Metabolism, Amsterdam University Medical Center, Amsterdam, The Netherlands

Search for other papers by Alberto M Pereira in
Google Scholar
PubMed
Close
,
Mehul Dattani London Centre for Pediatric Endocrinology and Diabetes at Great Ormond Street Children's Hospital and University College London Hospitals, London, UK

Search for other papers by Mehul Dattani in
Google Scholar
PubMed
Close
,
Diana Vitali SOD ITALIA (Italian Organization for Septo Optic Dysplasia and other Neuroendocrine Disorders), European Patient Advocacy Group, Rome, Italy

Search for other papers by Diana Vitali in
Google Scholar
PubMed
Close
,
Johan P de Graaf Dutch Pituitary Foundation, European Patient Advocacy Group, Nijkerk, The Netherlands

Search for other papers by Johan P de Graaf in
Google Scholar
PubMed
Close
, and
Nienke R Biermasz Adult Chair Main Thematic Group 6 Pituitary of Endo-ERN, Department of Medicine, Division of Endocrinology and Centre for Endocrine Tumors, Leiden University Medical Centre, Leiden, The Netherlands

Search for other papers by Nienke R Biermasz in
Google Scholar
PubMed
Close

Objective

The European Reference Network on Rare Endocrine Conditions (Endo-ERN) aims to organize high-quality healthcare throughout Europe, including care for pituitary adenoma patients. As surgery is the mainstay of treatment, we aimed to describe the current surgical practice and published surgical outcomes of pituitary adenoma within Endo-ERN.

Design and Methods

Systematic review and meta-analysis of studies reporting surgical outcomes of pituitary adenoma patients within Endo-ERN MTG6 pituitary reference centers between 2010 and 2019. A survey was completed by reference centers on their current surgical practice.

Results

A total of 18 out of 43 (42%) reference centers located in 7 of the 20 (35%) MTG6-represented countries published 48 articles. Remission rates were 50% (95% CI: 42–59) for patients with acromegaly, 68% (95% CI: 60–75) for Cushing’s disease, and 53% (95% CI: 39–66%) for prolactinoma. Gross total resection was achieved in 49% (95% CI: 37–61%) of patients and visual improvement in 78% (95% CI: 68–87). Mortality, hemorrhage, and carotid injury occurred in less than 1% of patients. New-onset hypopituitarism occurred in 16% (95% CI: 11–23), transient diabetes insipidus in 12% (95% CI: 6–21), permanent diabetes insipidus in 4% (95% CI: 3–6), syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in 9% (95% CI: 5–14), severe epistaxis in 2% (95% CI: 0–4), and cerebrospinal fluid leak in 4% (95% CI: 2–6). Thirty-five (81%) centers completed the survey: 54% were operated endoscopically and 57% were together with an ENT surgeon.

Conclusion

The results of this study could be used as a first benchmark for the outcomes of pituitary adenoma surgery within Endo-ERN. However, the heterogeneity between studies in the reporting of outcomes hampers comparability and warrants outcome collection through registries.

Open access
Yusaku Mori Division of Diabetes, Metabolism, and Endocrinology, Department of Internal Medicine, Showa University School of Medicine, Shinagawa, Tokyo, Japan

Search for other papers by Yusaku Mori in
Google Scholar
PubMed
Close
,
Hiroyuki Shimizu Division of Diabetes, Metabolism, and Endocrinology, Department of Internal Medicine, Showa University School of Medicine, Shinagawa, Tokyo, Japan
Maebashi Hirosegawa Clinic, Maebashi, Gunma, Japan

Search for other papers by Hiroyuki Shimizu in
Google Scholar
PubMed
Close
,
Hideki Kushima Division of Diabetes, Metabolism, and Endocrinology, Department of Internal Medicine, Showa University School of Medicine, Shinagawa, Tokyo, Japan

Search for other papers by Hideki Kushima in
Google Scholar
PubMed
Close
,
Tomomi Saito Division of Diabetes, Metabolism, and Endocrinology, Department of Internal Medicine, Showa University School of Medicine, Shinagawa, Tokyo, Japan

Search for other papers by Tomomi Saito in
Google Scholar
PubMed
Close
,
Munenori Hiromura Division of Diabetes, Metabolism, and Endocrinology, Department of Internal Medicine, Showa University School of Medicine, Shinagawa, Tokyo, Japan

Search for other papers by Munenori Hiromura in
Google Scholar
PubMed
Close
,
Michishige Terasaki Division of Diabetes, Metabolism, and Endocrinology, Department of Internal Medicine, Showa University School of Medicine, Shinagawa, Tokyo, Japan

Search for other papers by Michishige Terasaki in
Google Scholar
PubMed
Close
,
Masakazu Koshibu Division of Diabetes, Metabolism, and Endocrinology, Department of Internal Medicine, Showa University School of Medicine, Shinagawa, Tokyo, Japan

Search for other papers by Masakazu Koshibu in
Google Scholar
PubMed
Close
,
Hirokazu Ohtaki Department of Anatomy, Showa University School of Medicine, Shinagawa, Tokyo, Japan

Search for other papers by Hirokazu Ohtaki in
Google Scholar
PubMed
Close
, and
Tsutomu Hirano Division of Diabetes, Metabolism, and Endocrinology, Department of Internal Medicine, Showa University School of Medicine, Shinagawa, Tokyo, Japan

Search for other papers by Tsutomu Hirano in
Google Scholar
PubMed
Close

Nesfatin-1 is a novel anorexic peptide hormone that also exerts cardiovascular protective effects in rodent models. However, nesfatin-1 treatment at high doses also exerts vasopressor effects, which potentially limits its therapeutic application. Here, we evaluated the vasoprotective and vasopressor effects of nesfatin-1 at different doses in mouse models. Wild-type mice and those with the transgene nucleobindin-2, a precursor of nesfatin-1, were employed. Wild-type mice were randomly assigned to treatment with vehicle or nesfatin-1 at 0.2, 2.0 or 10 μg/kg/day (Nes-0.2, Nes-2, Nes-10, respectively). Subsequently, mice underwent femoral artery wire injury to induce arterial remodeling. After 4 weeks, injured arteries were collected for morphometric analysis. Compared with vehicle, nesfatin-1 treatments at 2.0 and 10 μg/kg/day decreased body weights and elevated plasma nesfatin-1 levels with no changes in systolic blood pressure. Furthermore, these treatments reduced neointimal hyperplasia without inducing undesirable remodeling in injured arteries. However, nesfatin-1 treatment at 0.2 μg/kg/day was insufficient to elevate plasma nesfatin-1 levels and showed no vascular effects. In nucleobindin-2-transgenic mice, blood pressure was slightly higher but neointimal area was lower than those observed in littermate controls. In cultured human vascular endothelial cells, nesfatin-1 concentration-dependently increased nitric oxide production. Additionally, nesfatin-1 increased AMP-activated protein kinase phosphorylation, which was abolished by inhibiting liver kinase B1. We thus demonstrated that nesfatin-1 treatment at appropriate doses suppressed arterial remodeling without affecting blood pressure. Our findings indicate that nesfatin-1 can be a therapeutic target for improved treatment of peripheral artery disease.

Open access
Rachel D C A Diniz
Search for other papers by Rachel D C A Diniz in
Google Scholar
PubMed
Close
,
Renata M Souza
Search for other papers by Renata M Souza in
Google Scholar
PubMed
Close
,
Roberto Salvatori Division of Endocrinology, Division of Endocrinology, Division of Hepatology, Division of Radiology, Diabetes and Metabolism, Federal University of Sergipe, Aracaju, Brazil

Search for other papers by Roberto Salvatori in
Google Scholar
PubMed
Close
,
Alex Franca Division of Endocrinology, Division of Endocrinology, Division of Hepatology, Division of Radiology, Diabetes and Metabolism, Federal University of Sergipe, Aracaju, Brazil

Search for other papers by Alex Franca in
Google Scholar
PubMed
Close
,
Elenilde Gomes-Santos
Search for other papers by Elenilde Gomes-Santos in
Google Scholar
PubMed
Close
,
Thiago O Ferrão Division of Endocrinology, Division of Endocrinology, Division of Hepatology, Division of Radiology, Diabetes and Metabolism, Federal University of Sergipe, Aracaju, Brazil

Search for other papers by Thiago O Ferrão in
Google Scholar
PubMed
Close
,
Carla R P Oliveira
Search for other papers by Carla R P Oliveira in
Google Scholar
PubMed
Close
,
João A M Santana
Search for other papers by João A M Santana in
Google Scholar
PubMed
Close
,
Francisco A Pereira
Search for other papers by Francisco A Pereira in
Google Scholar
PubMed
Close
,
Rita A A Barbosa
Search for other papers by Rita A A Barbosa in
Google Scholar
PubMed
Close
,
Anita H O Souza
Search for other papers by Anita H O Souza in
Google Scholar
PubMed
Close
,
Rossana M C Pereira
Search for other papers by Rossana M C Pereira in
Google Scholar
PubMed
Close
,
Alécia A Oliveira-Santos
Search for other papers by Alécia A Oliveira-Santos in
Google Scholar
PubMed
Close
,
Allysson M P Silva
Search for other papers by Allysson M P Silva in
Google Scholar
PubMed
Close
,
Francisco J Santana-Júnior
Search for other papers by Francisco J Santana-Júnior in
Google Scholar
PubMed
Close
,
Eugênia H O Valença
Search for other papers by Eugênia H O Valença in
Google Scholar
PubMed
Close
,
Viviane C Campos
Search for other papers by Viviane C Campos in
Google Scholar
PubMed
Close
, and
Manuel H Aguiar-Oliveira
Search for other papers by Manuel H Aguiar-Oliveira in
Google Scholar
PubMed
Close

Nonalcoholic fatty liver disease (NAFLD) is known to be associated with insulin resistance, atherosclerosis, and low serum IGF1 levels. We have described a large cohort of patients with isolated GH deficiency (IGHD) due to the c.57+1G→A mutation in the GHRH receptor gene. These subjects have increased insulin sensitivity (IS), delayed atherosclerosis, and normal longevity. We hypothesized that, despite visceral obesity, NAFLD would be absent or mild due to the increased IS. To assess the prevalence and severity of NAFLD in adult subjects with lifetime, congenital, untreated IGHD, we studied 22 IGHD adults and 25 controls (COs) matched for age and sex. NAFLD was assessed by a comprehensive liver function panel, and ultrasonographic pattern (hyperechogenic pattern, HP) coded as follows: 0, absent; 1, mild; 2, moderate; and 3, severe. Compared with COs, IGHD individual had lower serum IGF1 (P<0.0001), higher total cholesterol (P=0.027), lower prothrombin time (P=0.017), and similar activated partial thromboplastin time and fibrinogen values. Alanine transaminase (ALT) values were similar in the two groups, but aspartate transaminase was higher in IGHD (P=0.013). However, more IGHD subjects (7/22) than COs (3/23) had ALT above the upper limit of normal (P=0.044). The prevalence of NAFLD was higher in IGHD than COs (61 vs 29%, P=0.032), and the HP score was higher in IGHD than COs (P=0.041), but severe NAFLD was not observed in any IGHD (or CO) individual. Liver HP score is increased in lifetime, untreated, congenital IGHD, but the increase in transaminases is mild, suggesting a lack of advanced forms of NAFLD.

Open access
Michaela Keuper Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden

Search for other papers by Michaela Keuper in
Google Scholar
PubMed
Close

The crosstalk between macrophages (MΦ) and adipocytes within white adipose tissue (WAT) influences obesity-associated insulin resistance and other associated metabolic disorders, such as atherosclerosis, hypertension and type 2 diabetes. MΦ infiltration is increased in WAT during obesity, which is linked to decreased mitochondrial content and activity. The mechanistic interplay between MΦ and mitochondrial function of adipocytes is under intense investigation, as MΦ and inflammatory pathways exhibit a pivotal role in the reprogramming of WAT metabolism in physiological responses during cold, fasting and exercise. Thus, the underlying immunometabolic pathways may offer therapeutic targets to correct obesity and metabolic disease. Here, I review the current knowledge on the quantity and the quality of human adipose tissue macrophages (ATMΦ) and their impact on the bioenergetics of human adipocytes. The effects of ATMΦ and their secreted factors on mitochondrial function of white adipocytes are discussed, including recent research on MΦ as part of an immune signaling cascade involved in the ‘browning’ of WAT, which is defined as the conversion from white, energy-storing adipocytes into brown, energy-dissipating adipocytes.

Open access